Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy
Study Details
Study Description
Brief Summary
Ischemic optic neuropathy is among the most common causes of serious impaired vision in the middle-aged and elderly population in the western world. The current study focuses on a subgroup of ischemic optic neuropathy, the so-called non-arteritic ischemic optic neuropathy (NAION). Although the exact pathogenesis of NAION has not been fully clarified it is known that patients with cardio-vascular risk factors such as hypertension, diabetes mellitus and dyslipidemia have also an increased risk to develop NAION. Along this line of thought it has been shown that patients with a history of NAION in one eye have an increased risk to develop NAION also on the contralateral eye. However, clinical studies investigating ocular perfusion abnormalities in patients with NAION are sparse and even contradicting. Thus, the current study seeks to measure ocular blood flow parameters in patients with a history of NAION and compare it to healthy age-matched subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Patients with a history of NAION patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye |
Device: Dynamic Vessel Analyzer (DVA)
Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Retinal blood flow will be assessed using FDOCT.
Device: Optical coherence tomography (OCT)
Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
|
| Experimental: Healthy control subjects healthy age-and sex- matched control subjects |
Device: Dynamic Vessel Analyzer (DVA)
Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Retinal blood flow will be assessed using FDOCT.
Device: Optical coherence tomography (OCT)
Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
|
Outcome Measures
Primary Outcome Measures
- Flicker light induced hyperemia in retinal vessels [1 day]
Response of retinal vessels to increased neuronal activity assessed with flicker light
Secondary Outcome Measures
- Retinal vessel diameters [1 day]
Response of retinal vessel diameters to flicker light assessed with DVA
- Retinal oxygen saturation [1 day]
Retinal oxygen saturation measured with DVA
- Retinal blood flow [1 day]
Response of retinal blood flow to flicker light assessed with FDOCT
- Retinal nerve fiber layer thickness [1 day]
Retinal nerve fiber layer thickness measured using OCT
- Central retinal thickness [1 day]
Central retinal thickness using OCT
Eligibility Criteria
Criteria
Inclusion criteria for healthy subjects:
-
Men and women aged over 18 years
-
Non-smokers
-
Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
-
Normal ophthalmic findings, ametropy < 6 Dpt.
Inclusion criteria for patients with NAION:
-
Men and women aged over 18 years
-
History of NAION in one eye
-
Normal ophthalmic findings, ametropy < 6 Dpt.
-
Adequate visual acuity to allow participation in the ocular blood flow measurements
-
A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history for at least 30 days prior inclusion, if considered relevant by the investigator.
Any of the following will exclude a healthy subject from the study:
-
Current ocular disease or history of NAION
-
Presence or history of a severe medical condition as judged by the clinical investigator
-
Untreated Arterial hypertension
-
History or family history of epilepsy
-
Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
-
Best corrected visual acuity < 0.5 Snellen
-
Ametropy ≥ 6 Dpt
-
Pregnancy or planned pregnancy
-
Alcoholism or substance abuse
Any of the following will exclude a patient from the study:
-
Presence or history of a severe medical condition other NAION as judged by the clinical investigator
-
Untreated Arterial hypertension
-
History or family history of epilepsy
-
Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
-
Best corrected visual acuity < 0.5 Snellen in the non-affected eye
-
Ametropy ≥ 6 Dpt
-
Pregnancy, planned pregnancy
-
Alcoholism or substance abuse
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Clinical Pharmacology, Medical University of Vienna | Vienna | Austria | 1090 |
Sponsors and Collaborators
- Medical University of Vienna
Investigators
- Principal Investigator: Gerhard Garhöfer, MD, Department of Clinical Pharmacology, Medical University of Vienna
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OPHT-210917